Biobot
The world's first and most advanced wastewater intelligence platform
Cambridge, United States · Founded 2017 · $42.7M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 51–200
- Founded
- 2017
- Business Model
- B2B2C
- Total Funding
- $42.7M
- Last Round
- $13.5M Series AJun 2025
- Rounds
- 4
About
Biobot Analytics is the world's first and most advanced wastewater intelligence platform, transforming municipal sewer systems into population-level public health observatories. Founded in 2017 by Dr. Mariana Matus and Newsha Ghaeli as a spinout from MIT research on wastewater epidemiology, Biobot pioneered the commercial application of wastewater-based epidemiology as a public health surveillance tool. The company collects wastewater samples from utilities and municipal treatment plants across the United States, then analyzes them to detect and track over 50 human health biomarkers including viruses, pathogens, and high-risk substances such as opioids and fentanyl. During the COVID-19 pandemic, Biobot became a nationally recognized provider of early-warning wastewater surveillance data, serving more than 700 cities and institutions.
Summary
Biobot is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $42.7M in total across 4 rounds, most recently a $13.5M Series A round in Jun 2025. Investors include Valor Equity Partners, Thursday Ventures and General Catalyst.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jun 2025
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...

Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.

Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...


